SCTX Scribe Therapeutics Inc

Q: Which ETFs hold SCTX?

Scribe Therapeutics Inc (SCTX) is held by 1 fund tracked by ETFpeek as of 9 Oct 2026: ARKG (0.77%).

Which ETFs hold SCTX? Scribe Therapeutics Inc is held by 1 fund tracked by ETFpeek.

Held by 1 fund todayData as of 9 Oct 2026

HealthcareBiotechnology

$19.23

-1.3% 1y

$13.5052-week range$39.60

Market cap

$318M

CEO

Dr. Benjamin L. Oakes Ph.D.

Revenue · last 4 qtrs (-60.8% YoY)

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.

Currently Held By

ARK

ARKG

ARK Genomic Revolution ETF

Not held by the selected provider.

Insider Activity i

last 90 days

Net flow (90d):+$56.3M (17 without value)·20 BUY / 4 SELL·score ≥ 40

Date	Person	Action	Plan	Shares	Value	Score i
28 Jul 2026	Behzad Aghazadeh Director / Other	BUY	Discretionary	7,905	$144K	80
27 Jul 2026	Carl L Gordon Director / Other	BUY	Discretionary	1,000,000	$15.0M	100
27 Jul 2026	Bio Fund II, L.P. AH Director / Other	BUY	Discretionary	333,333	$5.0M	100
27 Jul 2026	Bio Fund II, L.P. AH Director / Other	SELL	Unknown	16,281,347 2 tranches	—	80
27 Jul 2026	Carl L Gordon Director / Other	SELL	Unknown	2,065,672	—	70
27 Jul 2026	Bio Fund II, L.P. AH Director / Other	BUY	Unknown	2,749,392 2 tranches	—	70
27 Jul 2026	Carl L Gordon Director / Other	BUY	Unknown	348,825	—	60
24 Jul 2026	Behzad Aghazadeh Director / Other	BUY	Discretionary	2,383,333 2 tranches	$36.1M	100
23 Jul 2026	Svetlana Lucas Chief Business Officer	BUY	Discretionary	3,000	$45K	80
23 Jul 2026	David Parrot Co-Founder & Scientific Advisor	BUY	Discretionary	1,333	$20K	60
23 Jul 2026	Benjamin L. Oakes Co-Founder, President, CEO & Chairman	BUY	Vested (RSU)	694,383 2 tranches	—	40
23 Jul 2026	Svetlana Lucas Chief Business Officer	BUY	Vested (RSU)	109,426	—	40

Net flow (90d):+$56.3M (17 without value)·20 BUY / 4 SELL·showing all trades

Date	Person	Action	Plan	Shares	Value	Score i
28 Jul 2026	Behzad Aghazadeh Director / Other	BUY	Discretionary	7,905	$144K	80
27 Jul 2026	Carl L Gordon Director / Other	BUY	Discretionary	1,000,000	$15.0M	100
27 Jul 2026	Bio Fund II, L.P. AH Director / Other	BUY	Discretionary	333,333	$5.0M	100
27 Jul 2026	Bio Fund II, L.P. AH Director / Other	SELL	Unknown	16,281,347 2 tranches	—	80
27 Jul 2026	Carl L Gordon Director / Other	SELL	Unknown	2,065,672	—	70
27 Jul 2026	Bio Fund II, L.P. AH Director / Other	BUY	Unknown	2,749,392 2 tranches	—	70
27 Jul 2026	Carl L Gordon Director / Other	BUY	Unknown	348,825	—	60
27 Jul 2026	Jennifer A Doudna Co-Founder & Scientific Advisor	SELL	Unknown	74,088	—	30
27 Jul 2026	Jennifer A Doudna Co-Founder & Scientific Advisor	BUY	Unknown	12,511	—	30
24 Jul 2026	Behzad Aghazadeh Director / Other	BUY	Discretionary	2,383,333 2 tranches	$36.1M	100
23 Jul 2026	Svetlana Lucas Chief Business Officer	BUY	Discretionary	3,000	$45K	80
23 Jul 2026	David Parrot Co-Founder & Scientific Advisor	BUY	Discretionary	1,333	$20K	60
23 Jul 2026	Benjamin L. Oakes Co-Founder, President, CEO & Chairman	BUY	Vested (RSU)	694,383 2 tranches	—	40
23 Jul 2026	Svetlana Lucas Chief Business Officer	BUY	Vested (RSU)	109,426	—	40
23 Jul 2026	Brett Staahl Co-Founder & VP of External Innovation	BUY	Vested (RSU)	19,385	—	30
23 Jul 2026	James Dean Watson Director / Other	BUY	Vested (RSU)	14,725	—	30
23 Jul 2026	David Parrot Co-Founder & Scientific Advisor	BUY	Vested (RSU)	109,426	—	30
23 Jul 2026	Joshua Bleharski Director / Other	BUY	Vested (RSU)	14,725	—	30
23 Jul 2026	Behzad Aghazadeh Director / Other	BUY	Vested (RSU)	14,725	—	30
23 Jul 2026	Carl L Gordon Director / Other	BUY	Vested (RSU)	14,725	—	30

Data: Finnhub (SEC Form 4 filings) · Score: ETFpeek heuristic

Trade History

13 trades

Date	Fund	Direction	Shares Changed	% Δ ETF i	% Δ Position i
8 Oct 2026	ARKG	BUYAdded	+14,431	+0.09%	1.73%
7 Oct 2026	ARKG	BUYAdded	+19,282	+0.07%	2.34%
6 Oct 2026	ARKG	BUYAdded	+47,411	-0.02%	5.79%
25 Sep 2026	ARKG	BUYAdded	+39,151	-0.16%	5.37%
24 Sep 2026	ARKG	BUYAdded	+143,265	+0.17%	20.71%
23 Sep 2026	ARKG	BUYAdded	+88,320	+0.10%	15.33%
22 Sep 2026	ARKG	BUYAdded	+61,867	-0.02%	12.92%
9 Sep 2026	ARKG	BUYAdded	+10,958	+0.07%	2.64%
1 Sep 2026	ARKG	BUYAdded	+10,743	+0.06%	2.61%
28 Aug 2026	ARKG	BUYAdded	+5,080	-0.05%	1.26%
19 Aug 2026	ARKG	BUYAdded	+5,614	+0.14%	1.54%
18 Aug 2026	ARKG	BUYAdded	+15,823	+0.02%	4.40%
29 Jul 2026	ARKG	BUYNew position	+351,661	+0.42%	100.00%
No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal.

SCTX Scribe Therapeutics Inc

Currently Held By

Insider Activity i

Trade History

More stocks in these funds